Pearce IP BioBlast w/e 10 May 2024
10 MAY 2024 | US | Valorum Biologics to Launch Xbrane and Stada’s Ranibizumab Biosimilar in the US On 10 May 2024, Xbrane and Stada announced the exclusive licensing agreement with US biosimilars specialist Valorum Biologics for their ranibizumab …